Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 3 1Phase 1 1

Status

Completed 3

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Carcinoma, Non-Small-Cell Lung 150Lung Neoplasms 58Pancreatic Neoplasms 34Neoplasms 20Neoplasm Metastasis 15Breast Neoplasms 15Adenocarcinoma of Lung 15Brain Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 13Glioblastoma 12Non-Squamous Non-Small Cell Lung Cancer 11Head and Neck Neoplasms 11Gliosarcoma 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Colorectal Neoplasms 8Carcinoma, Renal Cell 8Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Gallbladder Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 4Kidney Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

Carboplatin 44Paclitaxel 42Cisplatin 20Topotecan 17Gemcitabine 16Docetaxel 13Bevacizumab 13liposomal doxorubicin 7olaparib 6Cyclophosphamide 6pembrolizumab 5Surgical Procedures, Operative 5Filgrastim 5Etoposide 5Drug Therapy 5Amifostine 5sargramostim 4oregovomab 4catumaxomab 4anlotinib 4Imatinib Mesylate 4Hyperthermic Intraperitoneal Chemotherapy 4rucaparib 3pegfilgrastim 3niraparib 3ixabepilone 3aldesleukin 3Standard of Care 3Peripheral Blood Stem Cell Transplantation 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Ovarian Epithelial × Erlotinib Hydrochloride × Clear all
NCT00030446 2020-04-08

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Canadian Cancer Trials Group

Phase 2 Completed
50 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00059787 2015-12-01

Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

NCT00126542 2014-05-14

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡